New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
08:08 EDTVRXValeant acquires U.S. rights to Targretin from Eisai for $65M
Eisai and Valeant announced that Valeant has acquired U.S. rights for Targretin capsules and Targretin gel 1% from Eisai for $65M upfront, plus potential contingent payments based on certain milestones. As part of the transaction, which takes effect immediately, Eisai has transferred the New Drug Application for Targretin to Valeant, with Valeant assuming responsibilities for all regulatory obligations associated with the product in the United States. Eisai will retain its rights to Targretin outside of the United States and continue to meet the needs of its distribution partners outside of the United States.
News For VRX From The Last 14 Days
Check below for free stories on VRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:34 EDTVRXPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
07:19 EDTVRXValeant top pick in specialty pharmaceutical space, says Cantor
Subscribe for More Information
April 8, 2014
07:08 EDTVRXDrug deals increase to new high, Bloomberg says
M&A activity in the specialty pharmaceuticals industry has reached a new high after Mallinckrodt (MNK) recently bought Questcor (QCOR) for $5.6B, reported Bloomberg. Drugmakers from Actavis (ACT) to Valeant (VRX) are widening their suites of drugs through takeovers that immediately increased earnings with the help of lower corporate tax rates in countries such as Ireland. Reference Link
April 7, 2014
14:09 EDTVRXSun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use